This is a working overview of Endogenous peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
The identification of several specimens as juvenile T. rex has allowed scientists to document ontogenetic changes in the species, estimate the lifespan, and determine how quickly the animals would have grown. The Stygivenator holotype (LACM 28471, the "Jordan theropod"), possibly a juvenile T. rex, is estimated to have weighed only 30 kg (66 lb), while the largest adults, such as FMNH PR2081 (Sue) most likely weighed about 5,650 kg (12,460 lb). Histologic analysis of T. rex bones showed LACM 28471 had aged only 2 years when it died. Sue was initially estimated at 28 years old, an age which was at the time considered close to the maximum for the species, but the most recent studies estimate Sue's age at 27–33 years. Similarly, Trix (RGM 792.000) is estimated to have been at least 30 years old at time of death. Histology has also allowed the age of other specimens to be determined. Growth curves can be developed when the ages of different specimens are plotted on a graph along with their mass. A T. rex growth curve is S-shaped, with juveniles remaining under 1,800 kg (4,000 lb) until approximately 14 years of age, when body size began to increase dramatically. During this rapid growth phase, a young T. rex would gain an average of 600 kg (1,300 lb) a year for the next four years. At 18 years of age, the curve plateaus again, indicating that growth slowed dramatically. For example, only 600 kg (1,300 lb) separated the 28-year-old Sue from a 22-year-old Canadian specimen (RTMP 81.12.1).
Glutamate cysteine ligase catalytic subunit (GCLC, ~73 kDa) possesses all of substrate and cofactor binding sites and is responsible for all of the catalysis. Glutamate cysteine ligase modifier subunit (GCLM, ~31 kDa) has no enzymatic activity on its own but increases the catalytic efficiency of GCLC when complexed in the holoenzyme. In the majority of cells and tissues, the expression of GCLM protein is lower than GCLC and GCLM is therefore limiting in the formation of the holoenzyme complex. Thus, the sum total of cellular GCL activity is equal to the activity of the holoenzyme + the activity of the remaining monomeric GCLC. composed of a catalytic and a modulatory subunit. The catalytic subunit is necessary and sufficient for all GCL enzymatic activity, whereas the modulatory subunit increases the catalytic efficiency of the enzyme. Mice lacking the catalytic subunit (i.e., lacking all de novo GSH synthesis) die before birth. Mice lacking the modulatory subunit demonstrate no obvious phenotype, but exhibit marked decrease in GSH and increased sensitivity to toxic insults.
=== Polymerization === The ring-opening polymerization of butyrolactone gives polybutyrolactone. The resulting reverts to the monomer by thermal cracking. It is claimed that poly(GBL) is competitive with commercial biomaterial poly(4-hydroxybutyrate), or P4HB. It is further claimed that poly(GBL) is cheaper to make than P4HB, although both are bio-derived.
(2026) describe molars of Helarctos malayanus praemalayanus from the Pleistocene strata of the Tham Hai Cave (Vietnam), and interpret the fossil record from Southeast Asia as indicative of larger body size of Middle Pleistocene sun bears compared to their extant relatives. Probable fossil material of the Asian black bear, representing the first known record of a member of this lineage from northeastern Iberian Peninsula, is described from the Middle Pleistocene strata from Llers Quarry (Spain) by Rufí et al. (2026). Gutiérrez-Carbajal et al. (2026) reconstruct the evolutionary history of cave bears from southwestern Europe on the basis of data from enamel proteomic analysis, recovering Ursus dolinensis as a basal member of the cave bear lineage. Kochnev et al. (2026) study the variation of the size and shape of the hard palate and choanae of Ursus kanivetz and Ursus rossicus, and report possible evidence of a link between the hard palate form and the climate. A study on the ecology of cave bears from Galería 1 inside the Cueva de Guantes (Palencia, Spain) as indicated by isotopic composition of tooth enamel and bone collagen is published by Rodríguez-Franco et al. (2026). Hasegawa et al. (2026) study the distribution of brown bears in the Japanese Archipelago during the Late Pleistocene, reporting remains of exceptionally large individuals from Aomori, Nagano, Shizuoka and Oita. Estraviz-López et al.
Sources: en.wikipedia.org
Alexandra Lynn Medlin, Personal Assistant to British High Commissioner, Cape Town. Ian Adie Murray. For services to education in Murree, Pakistan. Ng Shui-Lai, . For services to welfare, Hong Kong. Edward George Pryor, , Principal Government Town Planner, Hong Kong. Olivia Margaret, Lady Roseveare. For services to education in Malawi Tatica Ernestine Scatliffe. For services to nursing and voluntary work in British Virgin Islands. Leonard Scott, lately Adviser on English Language, European Commission. Josephine Chang Siao Fong-fong. For services to the performing arts, Hong Kong. Neville Maxwell Alexander Smith, lately Chief Immigration Officer, Bermuda. Robert Soto. For services to Scuba diving, British Virgin Islands Edith Margaret Stewart, Matron, Bangkok Nursing Home, Thailand. Heather Themistocleous, Headmistress, Junior (Anglo-Cypriot) School, Nicosia. David Straiten Thomson. For welfare services to the community, Kenya. Valerie Ann Treitlein, Honorary British Consul, Conakry. Carlye Wai-Ling Tsui, . For services to the community, Hong Kong. Valentine Thomas Tudball. For services to the British community in Beirut. Michael Julian Christopher Waters, Deputy Political Adviser, Hong Kong. John Anthony Weaver. For services to the Anglican community, Sliema, Malta. The Reverend Colin Andrew Westmarland. For services to the Church of Scotland, Malta. Henry Winston Willans. For services to the British community, Uruguay. Angela Cheung Wong Wan Yiu, JP. For services to education and hospital administration, Hong Kong. Sister Annie Margaret Wong Kam-lin, Principal, St.
=== Menstrual disturbances === Spironolactone at higher doses can cause menstrual irregularities as a side effect in women, including metrorrhagia (intermenstrual bleeding), amenorrhea (absence of menstruation), and breakthrough bleeding. They are common during spironolactone therapy, with 10 to 50% of women experiencing them at moderate doses and almost all experiencing them at a high doses. For example, about 20% of women experienced menstrual irregularities with 50 to 100 mg/day spironolactone, whereas about 70% experienced menstrual irregularities at 200 mg/day. Most women taking moderate doses of spironolactone develop amenorrhea, and normal menstruation usually returns within two months of discontinuation. Spironolactone produces an irregular and anovulatory pattern of menstrual cycles. It is also associated with metrorrhagia and menorrhagia (heavy menstrual bleeding) in large percentages of women, as well as with polymenorrhea (short menstrual cycles). The medication reportedly has no birth control effect. The weak progestogenic activity of spironolactone has been suggested to be responsible for these effects, although not established, and spironolactone has been shown to possess insignificant progestogenic and antiprogestogenic activity even at high dosages in women. An alternative proposed cause is inhibition of 17α-hydroxylase and hence sex steroid metabolism by spironolactone and consequent changes in sex hormone levels. Indeed, CYP17A1 genotype is associated with polymenorrhea.
In the mitochondrion, pyruvate is oxidized by the pyruvate dehydrogenase complex to the acetyl group, which is fully oxidized to carbon dioxide by the citric acid cycle. Every "turn" of the citric acid cycle produces two molecules of carbon dioxide, one equivalent of ATP guanosine triphosphate (GTP) through substrate-level phosphorylation catalyzed by succinyl-CoA synthetase, as succinyl-CoA is converted to succinate, three equivalents of NADH, and one equivalent of FADH2. NADH and FADH2 are recycled (to NAD+ and FAD, respectively) by oxidative phosphorylation, generating additional ATP. The oxidation of NADH results in the synthesis of 2–3 equivalents of ATP, and the oxidation of one FADH2 yields between 1–2 equivalents of ATP. The majority of cellular ATP is generated by this process. Although the citric acid cycle itself does not involve molecular oxygen, it is an obligately aerobic process because O2 is used to recycle the NADH and FADH2. In the absence of oxygen, the citric acid cycle ceases. The generation of ATP by the mitochondrion from cytosolic NADH relies on the malate-aspartate shuttle (and to a lesser extent, the glycerol-phosphate shuttle) because the inner mitochondrial membrane is impermeable to NADH and NAD+. Instead of transferring the generated NADH, a malate dehydrogenase enzyme converts oxaloacetate to malate, which is translocated to the mitochondrial matrix. Another malate dehydrogenase-catalyzed reaction occurs in the opposite direction, producing oxaloacetate and NADH from the newly transported malate and the mitochondrion's interior store of NAD+.
== Special relativity == With the discovery of special relativity by Henri Poincaré and Albert Einstein, the energy was proposed to be a component of an energy-momentum 4-vector. Each of the four components (one of energy and three of momentum) of this vector is separately conserved across time, in any closed system, as seen from any given inertial reference frame. Also conserved is the vector length (Minkowski norm), which is the rest mass for single particles, and the invariant mass for systems of particles (where momenta and energy are separately summed before the length is calculated). The relativistic energy of a single massive particle contains a term related to its rest mass in addition to its kinetic energy of motion. In the limit of zero kinetic energy (or equivalently in the rest frame) of a massive particle, or else in the center of momentum frame for objects or systems which retain kinetic energy, the total energy of a particle or object (including internal kinetic energy in systems) is proportional to the rest mass or invariant mass, as described by the equation
A plant morphologist makes comparisons between structures in many different plants of the same or different species. Making such comparisons between similar structures in different plants tackles the question of why the structures are similar. It is quite likely that similar underlying causes of genetics, physiology, or response to the environment have led to this similarity in appearance. The result of scientific investigation into these causes can lead to one of two insights into the underlying biology:
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
Peptide content is usually measured by reverse-phase high-performance liquid chromatography, while copper is measured by atomic spectroscopy. Mass spectrometry can confirm the peptide identity and detect copper adducts. Combining these methods gives a more complete picture.